| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Garofalo Health Care S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.38 |
| 52 Week High | €5.78 |
| 52 Week Low | €4.34 |
| Beta | 0.45 |
| 11 Month Change | -0.37% |
| 3 Month Change | 7.17% |
| 1 Year Change | 19.29% |
| 33 Year Change | -6.60% |
| 5 Year Change | 9.46% |
| Change since IPO | 51.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| GHC | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -4.3% | 5.6% | -1.4% |
| 1Y | 19.3% | 28.6% | 11.8% |
Return vs Industry: GHC underperformed the German Healthcare industry which returned 26.8% over the past year.
Return vs Market: GHC exceeded the German Market which returned 13.9% over the past year.
Price Volatility
| GHC volatility | |
|---|---|
| GHC Average Weekly Movement | 3.6% |
| Healthcare Industry Average Movement | 3.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GHC has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GHC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 2,770 | Maria Garofalo | www.garofalohealthcare.com |
Garofalo Health Care S.p.A., together with its subsidiaries, operates healthcare clinics in Italy. It operates through Hospital and Social/Dependency Care segments. The company offers high-complexity surgery, medium- and low-complexity surgery, emergency surgery, medicine, clinical and interventional cardiology, and extended and intensive care units, as well as motor, neurological, cardiac, and nutritional rehabilitation.
Garofalo Health Care S.p.A. Fundamentals Summary
| GHC fundamental statistics | |
|---|---|
| Market cap | €485.32m |
| Earnings (TTM) | €23.80m |
| Revenue (TTM) | €431.14m |
20.4x
P/E Ratio1.1x
P/S RatioIs GHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GHC income statement (TTM) | |
|---|---|
| Revenue | €431.14m |
| Cost of Revenue | €337.77m |
| Gross Profit | €93.37m |
| Other Expenses | €69.57m |
| Earnings | €23.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.27 |
| Gross Margin | 21.66% |
| Net Profit Margin | 5.52% |
| Debt/Equity Ratio | 55.4% |
How did GHC perform over the long term?
See historical performance and comparison